Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
The approved distribution plan is intended to return settlement funds to eligible consumers who purchased specified generic drugs between May 2009 and December 2019. The manufacturers’ settlements totaled approximately $96.5 million.
Review vendor, distribution, and customer agreements for terms that could facilitate coordination with competitors, including exchanges of nonpublic pricing, market-allocation arrangements, or restrictions on independent pricing decisions. Check pharmaceutical supply and distribution contracts for clear independent-pricing obligations, limits on sharing competitively sensitive information, and audit rights supporting antitrust compliance. Employee and consultant agreements and policies should also address competitor-contact rules, trade association participation, escalation of suspected collusion, and cooperation with investigations.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"The coalition previously announced settlements with the manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"defendants used terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion."
"Attorney General Tong, along with the Attorneys General of 47 other states and territories"
"09/22/2026"
$96.5M
Oregon and a multistate coalition announced a plan to distribute settlement funds to people who paid inflated prices for certain generic drugs. The release says a federal court granted preliminary approval of the distribution plan this month; it does not give the date of that approval, and the reported conduct concerns alleged antitrust violations rather than a privacy violation.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
Connecticut Attorney General William Tong and a 23-state coalition obtained a court ruling declaring unlawful federal immigration-enforcement conditions placed on Congressionally authorized public safety grants. The court permanently enjoined the federal government from implementing or enforcing those conditions; the release does not describe a privacy violation or monetary penalty.
Connecticut Attorney General William Tong co-led a bipartisan coalition of 45 attorneys general urging Congress to pass the Kids Online Safety Act. This was a legislative advocacy effort, not a new enforcement action; the release discusses prior investigations into platforms’ effects on children and a separate Meta settlement.
Connecticut Attorney General William Tong joined a coalition of 24 attorneys general and two governors in opposing proposed changes to the 2030 Census. The coalition argued the proposal would exclude people from the count, remove demographic questions, and replace the usual-residence standard; this was a comment-letter action, not a penalty or enforcement order.
Connecticut Attorney General William Tong joined attorneys general from 17 states in an amicus brief urging the New York Court of Appeals to preserve state authority to pursue fraud cases. The underlying civil case alleges that Donald Trump and his co-defendants inflated asset values to obtain better loan and insurance terms; this press release announces advocacy, not a new enforcement order or penalty.